Evidence map›Paper›PMID 42589505›Full record

ArticleInternational journal of molecular sciences2026

Immuno-Inflammatory Profiling and Complement Activation in Fabry Disease: A Cross-Sectional Study.

Mercedes Peña-Rodríguez, Nuria Bara-Ledesma, Martin Fabregate, Montserrat Morales Conejo, Fernando Domínguez-Rodríguez, Borja Merino-Ortiz, Sinziana Stanescu, Pedro Ruiz-Sala, Andrés González García, Amaya Belanger-Quintana and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mercedes Peña-RodríguezInternal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Nuria Bara-LedesmaInternal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0003-4522-8511
Martin FabregateInternal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-7378-4868
Montserrat Morales ConejoUnit for Congenital Metabolic Diseases and Other Rare Diseases, Internal Medicine Department, Reference Center for Inherited Metabolic Disease-MetabERN, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Fernando Domínguez-RodríguezCardiology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain.
Borja Merino-OrtizInternal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0003-2433-7751
Sinziana StanescuFaculty of Medicine and Health Sciences, Universidad de Alcalá (UAH), 28805 Alcalá de Henares, Spain.ORCID 0000-0003-0340-4580
Pedro Ruiz-SalaCentre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-1785-4988
Andrés González GarcíaInternal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-7367-9523
Amaya Belanger-QuintanaFaculty of Medicine and Health Sciences, Universidad de Alcalá (UAH), 28805 Alcalá de Henares, Spain.ORCID 0000-0003-0102-8956
Mónica López-RodríguezInternal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-4594-1483

Funding

Fundación Mutua Madrileña AP177092021
6 · The paper itself

Abstract

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by α-galactosidase A deficiency, leading to glycosphingolipid accumulation and progressive organ damage. Beyond substrate storage, low-grade inflammation and complement activation have been increasingly implicated in FD pathogenesis, yet a comprehensive characterization of this immuno-inflammatory profile is lacking. In this exploratory cross-sectional study, fifteen patients with FD and fifteen age- and sex-matched healthy controls (HCs) were assessed using a broad panel of systemic inflammatory, humoral immunity/complement, hematological, and endothelial biomarkers, integrated through univariate analysis (Cliff's delta, δ), penalized least absolute shrinkage and selection operator (LASSO) regression, and unsupervised hierarchical clustering. Fibrinogen (δ = 0.60, 95% confidence interval (CI) 0.24-0.88), sTNFR2 (δ = 0.48, 95% CI 0.08-0.80), complement C4 (δ = 0.53, 95% CI 0.13-0.84), and lymphocyte count (δ = 0.52, 95% CI 0.15-0.85) showed the largest between-group effect sizes among the immuno-inflammatory biomarkers assessed, with higher levels in FD. Fibrinogen and sTNFR2 were the most stable predictors in LASSO bootstrap resampling (selected in 75.0% and 69.5% of iterations, respectively), and unsupervised clustering segregated FD from HCs with high accuracy (90% FD enrichment in the high-biomarker cluster;

Indexed as

Complement ActivationFabry DiseaseInflammationAdultBiomarkersCase-Control StudiesComplement C4Cross-Sectional StudiesFemaleFibrinogenHumansMaleMiddle AgedReceptors, Tumor Necrosis Factor, Type IIBiomarkersComplement C4FibrinogenReceptors, Tumor Necrosis Factor, Type IIclustering analysiscomplement systemFabry diseasefibrinogenLASSOlow-grade systemic inflammationlysosomal storage disorderssoluble TNF receptor 2

Identifiers

PMID42589505
PMCPMC13466531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.